Top Markets
Coin of the day
Handa Pharmaceuticals, Inc. Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc.

6620
Rangering i aksjer #13397
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
Aksjekurs
$2.95
Markedsverdi
$491.95M
Endring (1 dag)
9.94%
Endring (1 år)
8.06%
Land
TW
Handel Handa Pharmaceuticals, Inc. (6620)

Kategori

EPS for Handa Pharmaceuticals, Inc. (6620)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Handa Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Handa Pharmaceuticals, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter